What's Happening?
Circio, based in Oslo, Norway, and GenAssist, located in Suzhou, China, have announced a research collaboration aimed at developing advanced gene therapy solutions for genetic muscle diseases. The partnership focuses on creating circVec-enhanced AAV vectors
designed for in vivo cell therapy and systemic gene therapy at lower doses. This initiative addresses the high dosing requirements and associated toxicity of current gene therapies. By combining Circio's circular RNA technology with GenAssist's tissue-specific AAV platform, the collaboration seeks to enhance muscle-specific expression while minimizing systemic dosing and off-target effects. The partnership also explores the potential for developing in vivo CAR T candidates for oncology and autoimmune diseases, utilizing GenAssist's T-cell targeting capabilities.
Why It's Important?
This collaboration is significant as it targets a major unmet medical need in the field of genetic muscle diseases, where existing therapies often require high doses that can lead to severe side effects. By reducing the necessary dosage and enhancing tissue-specific targeting, the partnership aims to improve the safety and efficacy of gene therapies. This could lead to more accessible and effective treatments for patients suffering from these conditions. Additionally, the exploration of CAR T candidates for cancer and autoimmune diseases could expand the therapeutic applications of this technology, potentially benefiting a broader range of patients and advancing the field of genetic medicine.
What's Next?
The collaboration will involve the production and testing of novel AAVs that combine GenAssist's T-cell targeting with Circio's circVec expression cassette. These AAVs will undergo in vitro and in vivo testing, and successful candidates will be nominated for preclinical development. The partnership aims to evaluate the synergistic effects of the enhanced circVec expression with targeted capsids and promoters. If successful, this could lead to new therapeutic avenues and partnerships, particularly in regions like China, which offers accelerated pathways for clinical data establishment.
